23.04.2026

Cheryl Arrowsmith Receives 2026 AACR Award for Outstanding Achievement in Chemistry in Cancer Research

by: SGC

The American Association for Cancer Research has recognized Cheryl H. Arrowsmith, Chief Scientist of the Structural Genomics Consortium (SGC), Senior Scientist at the Princess Margaret Cancer Centre, University Health Network, and Professor in the Department of Medical Biophysics at the University of Toronto, with the 2026 AACR Award for Outstanding Achievement in Chemistry in Cancer Research.

13.04.2026

Structural Genomics Consortium appoints global leadership team to scale Target 2035

by: SGC

Toronto, Canada — April 13 — The Structural Genomics Consortium (SGC) today announced that it will expand its leadership team to help accelerate the next phase of Target 2035, a global effort to develop a pharmacological modulator for every human protein by 2035.

Join MAINFRAME

A new international network of machine learning researchers, computational chemists, and data scientists. Membership is free and provides access to curated datasets for model testing and benchmarking.

BEACON

Target 2035 collaborates with BEACON, the new benchmarking super-consortium comprising CACHE, DREAM, CASP, OpenADMET, to provide a platform for computational scientists to benchmark hit-finding algorithms in real world settings, with experimental testing of model predictions.

07.04.2026

New open science initiative to validate novel fertility targets and enable future therapeutic strategies

by: SGC

Frankfurt, Germany – April 7, 2026 — PREVENT (Precision REproductive and contraceptiVE target discovery NeTwork), a new multidisciplinary initiative focused on expanding non-hormonal contraceptive strategies, has officially launched. The program brings together expertise across reproductive biology, chemical biology, structural biology, and medicinal chemistry to identify and validate novel targets involved in fertility. 

31.03.2026

Insights and Lessons Learned: Highlights from the MAINFRAME 2026 Symposium

by: SGC

A Community Taking Shape in AI-Driven Drug Discovery

In March 2026, the first MAINFRAME Symposium brought together more than 180 researchers from academia and industry in Barcelona, marking a defining moment for a rapidly emerging field. What began just over a year ago as an idea to create an open, global community focused on machine learning for drug discovery has quickly evolved into a growing international network now spanning more than 250 members across 45+ countries.

Postdoctoral Research Associate (SGC-UNC)

Position Information

A global higher education leader in innovative teaching, research and public service, the University of North Carolina at Chapel Hill consistently ranks as one of the nation’s top public universities and is among is the top ten research universities in the nation for federal research expenditures as well as for federally funded social and behavioral sciences research and development.

Target 2035 Fellow (Postdoctoral Researcher – Machine Learning for Drug Discovery)

Position Description

Location: Toronto, Ontario, Canada (Split between The Hospital for Sick Children and the Structural Genomics Consortium).
Term: Multi-year project (Estimated 2026-2028).
Supervision: Dr. Michal Koziarski (SickKids/UofT) and Dr. Matthieu Schapira (SGC/UofT).
Industry partnership: A Senior Scientific Director, Computational Drug Discovery from a large pharmaceutical company agreed to act as Industry Mentor.

Subscribe to